相关实验视频
Updated: Sep 16, 2025

06:08
A Novel Method: Super-selective Adrenal Venous Sampling
Published on: September 15, 2017
23.6K
亚临床原发性阿尔多和主要心血管不良事件:基于人口的长度队列研究
Rémi Goupil1,2,3, Louis-Charles Desbiens2, Amel Merabtine3
1Hôpital de Sacré-Cœur de Montréal, CIUSSS-du-Nord-de-l'île-de-Montréal, Montreal, QC, Canada (R.G., F.M.).
Circulation
|July 9, 2025
概括
亚临床原发性阿尔多斯特症,以低或高阿尔多斯特与的比率表示,增加心血管事件的风险. 这种关联与血压无关,因此需要有针对性的查和治疗.
科学领域:
- 心血管医学
- 内分泌学
- 流行病学
背景情况:
- 主要的阿尔多斯特 (PA) 与心血管事件的增加有关.
- 亚临床PA是一种较温和的形式,但其与心血管风险的关联尚不清楚.
研究的目的:
- 调查亚临床原发性阿尔多斯特隆症标志物与主要心血管不良事件 (MACE) 之间的关联.
主要方法:
- 2017年来自CARTaGENE队列的加拿大成年人 (40-69岁) 的前性研究
- 在基线测量了阿尔多素,素和阿尔多素与素的比率 (ARR).
- 与MACE (心肌梗塞,中风,心力衰竭住院,心血管死亡) 的管理数据库连接,随访时间中位数为10. 8年.
主要成果:
- 较低的蛋白和较高的ARR与MACE风险的增加有关,而这与血压无关.
- 确定了最佳值:氨酸≤4.0 ng/ l,每ng/ l的ARR≥70 pmol/ l预测更高的MACE风险.
- 单独阿尔多的度与MACE没有显著的关联.
结论:
- 通过特定的蛋白和ARR水平识别的亚临床血压与MACE风险增加有关,不依赖于血压.
- 需要进一步的研究来确认早期发现和治疗亚临床肺炎是否可以降低心血管风险.
更多相关视频
相关概念视频
Hypertension III: Clinical Manifestations and Diagnostic Studies
54
Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
54
Antihypertensive Drugs: Action of β1 Blockers
618
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
618
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
516
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
516
Hypertension and Regulation of Blood Pressure
3.1K
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
3.1K
Hypertension II: Pathophysiology
90
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
90
Heart Failure II: Pathophysiology
51
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
51

